SCHEDULE: Orbis Investment Management Discloses Genmab Stake

Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have jointly filed a Schedule 13G, reporting beneficial ownership of 5.5% of Genmab A/S common stock as of March 31, 2026.

Summary

• Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd have filed an amendment to their Schedule 13G filing.
• The filing indicates beneficial ownership of 3,557,484 shares of Genmab A/S common stock.
• This represents 5.5% of the class of securities.
• The date of the event requiring this filing is March 31, 2026.
• Orbis Investment Management Ltd holds 3,549,674 shares, with sole voting and dispositive power.
• Allan Gray Australia Pty Ltd holds 7,810 shares, with sole voting and dispositive power.
• Both entities are classified as Non-U.S. Institutions (FI) equivalent to Investment Advisers (IA).
• The filing states that neither entity is part of a group for the purposes of Section 13(d)(3) and disclaims beneficial ownership of shares held by the other.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of beneficial ownership by investment management firms and does not provide new operational or financial information about Genmab A/S itself.

Positives

• Significant stake disclosed, indicating investor confidence in Genmab A/S.
• Clear reporting of beneficial ownership by two distinct investment entities.
• The filing is up-to-date as of March 31, 2026.

Negatives

• The filing does not contain any negative financial or operational information about Genmab A/S itself, as it is a disclosure of ownership.
• No specific details are provided regarding the rationale behind the investment or any strategic intentions beyond standard investment management.

Risks

• The filing does not explicitly mention any risks related to Genmab A/S. The risks inherent in holding a 5.5% stake in a publicly traded company, such as market volatility and potential changes in company performance, are implied but not detailed.
• The disclaimer that neither reporting person is part of a group could imply potential divergence in future strategies or actions, though this is speculative.

Future Outlook

The filing does not contain forward-looking statements or guidance from Genmab A/S. It is a disclosure of ownership by investment management firms.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are standard disclosures for institutional investors crossing certain ownership thresholds. The significant stake held by Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd in Genmab A/S, a prominent biotechnology company, reflects ongoing institutional interest in the sector. This filing is typical for large asset managers and does not inherently signal a change in Genmab's strategic direction, but rather an affirmation of its position within the portfolios of these investment firms.

Comparison to Industry Standards

• The ownership percentage of 5.5% by Orbis Investment Management Ltd is a substantial minority stake, common for institutional investors in the biotechnology sector.
• Filing a Schedule 13G is the standard procedure for passive investors who acquire more than 5% of a company's stock, aligning with regulatory requirements for entities like Orbis and Allan Gray Australia.
• The classification as 'Non-U.S. Institution (FI) equivalent to Investment Adviser (IA)' is a common designation for international investment firms operating under specific regulatory frameworks.

Stakeholder Impact

• Shareholders: The disclosure confirms significant institutional ownership, which can be viewed positively for stability, but does not directly impact current share value without further context.
• Management of Genmab A/S: Awareness of substantial institutional holders is standard and does not necessitate immediate action, but may influence future investor relations efforts.
• Regulators: Compliance with SEC reporting requirements is maintained.

Next Steps

• Orbis Investment Management Ltd and Allan Gray Australia Pty Ltd will continue to hold their shares in Genmab A/S, subject to their investment strategies.
• Further amendments to this Schedule 13G will be filed if there are material changes in beneficial ownership.

Key Dates

Keywords

Genmab A/S, Schedule 13G, Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, Beneficial Ownership, Common Stock, Investment Management, SEC Filing, Securities Exchange Act